

1. Arterburn D, Sofer T, Boudreau DM, et al. Long-Term Weight Change after Initiating Second-Generation Antidepressants. *J Clin Med*. 2016 Apr 13;5(4):48. doi:10.3390/jcm5040048. PMID: 27089374.
2. Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. *Biol Psychiatry*. 2007 Aug 15;62(4):345–354. doi: 10.1016/j.biopsych.2006.09.023. PMID: 17223086.
3. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. *Stroke*. 1994 Jun; 25(6):1099–104. doi: 10.1161/01.str.25.6.1099. PMID: 8202964.
4. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. *JAMA*. 2003 Jun 18; 289(23):3106–16. doi: 10.1001/jama.289.23.3106. PMID: 12813116.
5. Bigger JT, Giardina EG, Perel JM, et al: Cardiac antiarrhythmic effect of imipramine hydrochloride. *N Engl J Med*. 1977 Jan 27; 296(4):206–208. doi: 10.1056/NEJM197701272960407. PMID:318730.
6. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. *Ann Rheum Dis*. 2008 Apr;67(4):536–41. doi:10.1136/ard.2007.071522. PMID: 17644548.
7. Clodagh P, Duffy R, Mahon J, et al. Bones of Contention: A Comprehensive Literature Review of Non-SSRI Antidepressant Use and Bone Health. *J Geriatr Psychiatry and Neurol*. 2020;33(6):340–352. doi:10.1177/0891988719882091. PMID: 31665962.
8. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. *Clin Ther*. 2002 Apr;24(4):662–72. doi:10.1016/s0149-2918(02)85141-4. PMID: 12017410.
9. Duloxetine (Cymbalta). Package insert. Eli Lilly and Company; 2010.
10. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. *Pain* 2007 Dec 5;132(3):237–251. doi:10.1016/j.pain.2007.08.033. PMID: 17920770.
11. Elliott AJ, Uldall KK, Bergam K, et al. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. *Ann Pharmacother*. 2005 Jan;29(1):141–5. doi:10.1345/aph.1E248. PMID: 15562140.
12. Fornasari D. Pharmacotherapy for Neuropathic Pain: A Review. *Pain Ther*. 2017 Dec;6(Suppl 1):25–33. doi:10.1007/s40122-017-0091-4. PMID: 29178034.
13. Gelenberg AJ, Freeman MP, Markowitz JC, et al. American psychiatric association practice guideline for the treatment of patients with major depressive disorder. 2010. Accessed January 5, 2022. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
14. Ghaeli P, Shahsavan E, Mesbahi M, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. *J Clin Psychopharmacol*. 2004 Aug;24(4):386–8. doi:10.1097/01.jcp.0000132441.27854.0d. PMID: 15232329.
15. Giardina EG, Barnard T, Johnson L, et al. The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations. *J Am Coll Cardiol*. 1986 Jun; 7(6):1363–9. doi: 10.1016/s0735-1097(86)80158-9. PMID:3711494.
16. Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. *JAMA*. 1983 Oct 21; 250(15):1997–2001. PMID: 6620499.
17. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA*. 2002 Aug 14; 288(6):701–9. doi:10.1001/jama.288.6.701. PMID:12169073.
18. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. *Neurology* 1984 Aug; 34(8):1092– 1094. doi:10.1212/wnl.34.8.1092. PMID:6431314.
19. Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. *Kidney Int*. 2012 Feb;81(3):247–255. doi:10.1038/ki.2011.358. PMID:22012131.
20. Hovorka J, Herman E, Nemcova I. Treatment of interictal depression with citalopram in patients with epilepsy. *Epilepsy Behav*. 2000 Dec; 1(6):444–447. doi:10.1006/ebep.2000.0123. PMID: 12737834.
21. Isocarboxazid (Marplan). Package insert. Amneal Pharmaceuticals; 2007.
22. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? *Epilepsy Behav* 2000 Apr; 1(2):100–105. doi: 10.1006/ebep.2000.0050. PMID: 12609138.

23. Kingshuk L, Shetty HM, Paramel A, et al. Sexual dysfunction with the use of antidepressants in a tertiary care mental health setting – a retrospective case series. *J Pharmacol Pharmacother*. 2011 Apr-Jun;2(2):128-131. doi:10.4103/0976-500X.81913. PMID: 21772780.
24. Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma. Assessment and appropriate precautions. *Psychosomatics* 1987;28(3):145-148. doi:10.1016/s0033-3182(87)72555-9. PMID: 3432532
25. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. *Psychosom Med*. May-Jun 1997;59(3):241-50. doi: 10.1097/00006842-199705000-00007. PMID: 9178335.
26. Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. *Cochrane Database Syst Rev* 2005 Jul 20;(3):CD002919. doi:10.1002/14651858.CD002919.pub.2 PMID: 16034880
27. Nefazodone (Serzone). Package insert. Bristol-Myers Squibb Company; 2001.
28. Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. *Am J Psychiatry*. 1999 Jul; 156(7):1024–8. doi: 10.1176/ajp.156.7.1024. PMID: 10401446.
29. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache*. 2005 Feb;45(2):144-52. doi:10.1111/j.1526-4610.2005.05.029.x. PMID: 15705120.
30. Phenelzine (Nardil). Package insert. Pfizer; 2007.
31. Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. *Psychosomatics*. 2003 May-Jun; 44(3):216–21. doi: 10.1176/appi/psy/44.3.216. PMID: 12724503.
32. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. *Am J Psychiatry*. 2000 Mar; 157(3):351–9. doi: 10.1176/appi.ajp.157.3.351.
33. Roopan S, Larsen E. (2017). Use of antidepressants in patients with depression and comorbid diabetes mellitus: A systematic review. *Acta Neuropsychiatrica*. 2017 June;29(3):127-139. doi:10.1017/neu.2016.54 PMID: 27776567.
34. Schmitz B. Antidepressant drugs: indications and guidelines for use in epilepsy. *Epilepsia*. 2002;43 Suppl 2:14-8. doi:10.1046/j.1528-1157.2002.043s2014.x. PMID:11903477.
35. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? *Am J Med*. 2006 Feb; 119(2):113–6. doi: 10.1016/j.amjmed.2005.03.044. PMID: 16443409.
36. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. *Arch Gen Psychiatry*. 2005 Jul; 62(2):792-8. doi:10.1001/archpsyc.62.7.792. PMID:15997021.
37. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. *Mov Disord*. 2000 Sept;15(5):986–989. doi:10.1002/1531-8257(200009)15:5<986::aid-mds1034>3.0.co;2-i. PMID: 11009210.
38. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. *J Clin Psychiatry*. 1998 Oct;59(10):502-8. doi: 10.4088/jcp.v59n1002. PMID: 9818630.
39. Tranylcypromine (Parnate). Package insert. Concordia Pharmaceuticals; 2018.
40. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. *Br J Psychiatry*. 2007 Jun; 190:460–6. doi:10.1192/bjp.bp.106.028647. PMID: 17541103.
41. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. *J Clin Psychiatry*. 1993 Dec; 54(12):459–65. PMID: 8276736.
42. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. *Psychol Med Monogr Suppl*. 1989;16:i-iii,1-40. doi: 10.1017/s0264180100000709. PMID: 2690161.
43. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. *Stroke*. 2000 Aug; 31(8):1829–32. doi: 10.1161/01.str.31.8.1829. PMID: 10926942.
44. Williams K, Reynolds MF. Sexual dysfunction in major depression. *CNS Spectr*. 2006 Aug;11(8 Suppl 9):19-23. doi: 10.1017/s1092852900026729. PMID:16871134.
45. Yeragani VK, Pesce V, Jayaraman A, et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. *Biol Psychiatry*. 2002 Sep 1; 52(2):418–429. doi: 10.1016/s0006-3223(02)01394-x. PMID:12242058.

46. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications, and mechanisms underlying drug-induced weight gain in psychiatric patients. *J Psychiatr Res.* May-June 2003;37(3):193-220. doi: 10.1016/s0022-3956(03)00018-9. PMID: 12650740.
47. Centre for Addiction and Mental Health. (n.d.) *Anti-anxiety medications (benzodiazepines)*. Mental Illness & Addiction Index. <https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/anti-anxiety-medications-benzodiazepines>
48. Harvard Health Publishing. (2020, Mar 25). *Coming off your medication can cause antidepressant withdrawal-and could you set up for a relapse of depression*. Diseases & Conditions. <https://www.health.harvard.edu/diseases-and-conditions/going-off-antidepressants>
49. Harvard Health Publishing. (2020, Jan 29). *How to taper off your antidepressant*. Diseases & Conditions. <https://www.health.harvard.edu/diseases-and-conditions/how-to-taper-off-your-antidepressant>
50. Keks N, Hope J, Keogh S. Switching and stopping antidepressants. *Aust Prescr.* 2016 Jun;39(3):76-83. doi:10.18773/austprescr.2016.039. PMID: 27346915.
51. Lader M, Tylee A, Donoghue. Withdrawing benzodiazepines in primary care. *CNS Drugs.* 2009;23(1):19-34. doi:10.2165/0023210-200923010-00002. PMID: 19062773.
52. Pregabalin (Lyrica). Package insert. Pfizer;2018.
53. Tanzi MG. Stopping antidepressants: Clinical considerations. *Antidepressants.* 2016 May 1;22(5):38-39.
54. Vahratian A, Blumberg SJ, Terlizzi EP, et al. Symptoms of Anxiety or Depressive Disorder and Use of Mental Health Care Among Adults During the COVID-19 Pandemic – United States. August 2020-February 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:490-494. doi:http://dx.doi.org/10.15585/mmwr.mm7013e2.
55. Wagener, D. (2022, Mar 4). *Gabapentin Withdrawal Symptoms, Signs & Side Effects*. Neurontin Abuse. <https://americanaddictioncenters.org/neurontin-abuse/gabapentin-cause-withdrawal-symptoms>
56. Zwiebel SJ, Viguera AC. Discontinuing antidepressants: Pearls and pitfalls. *Cleve Clin J Med.* 2022 Jan 4;89(1):18-26. doi: 10.3949/ccjm.89a.21020. PMID: 34983798.
57. Bobo WV. Switching Antipsychotics: Why, When, and How? *Psychiatric Times.* 2013 Mar 3;30(3). <https://www.psychiatrictimes.com/view/switching-antipsychotics-why-when-and-how>
58. Dennis JF, Gittner LS, Payne JD, et al. Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013-2018. *BMC Psychiatry.* 2020 Oct 1;20,483. doi:10.1186/s12888-020-02895-4.
59. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching Between Second-Generation Antipsychotics. *CNS Drugs.* 2012 Aug 29;19:27-42. doi:10.2165/00023210-200519010-00003.
60. Keks N, Hope J, Keogh S. Switching and stopping antidepressants. *Aust Prescr.* 2016 Jun;39(3):76-83. doi:10.18773/austprescr.2016.039. PMID:27346915.
61. Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. *Aust Prescr.* 2019 Oct;42(5):152-157. doi:10.18773/austprescr.2019.052. PMID: 31631928.
62. National Institute for Health and Care Excellence (2018). Depression in adults: recognition and management (NICE Guideline CG90). Available at: <https://www.nice.org.uk/guidance/cg90>
63. Soreide KK, Ward KM, Bostwick JR, et al. Strategies and Solutions for Switching Antidepressant Medications. *Psychiatric Times.* 2017 Dec 15;34(12). <https://www.psychiatrictimes.com/view/strategies-and-solutions-switching-antidepressant-medications>
64. Ansara, Elayne D. "Management of Treatment-Resistant Generalized Anxiety Disorder." *The Mental Health Clinician* 2020 Nov; 10(6): 326-334. Published on Nov 5, 2020. doi: [10.9740/mhc.2020.11.326](https://doi.org/10.9740/mhc.2020.11.326)
65. Bostwick, Jolene R. (2020) *College of Psychiatric and Neurologic Pharmacists 2020-2021 Psychiatric Pharmacotherapy Review*. College of Psychiatric and Neurologic Pharmacists. Chapter 1: Anxiety and anxiety-Related Disorders, pg 16-85.
66. Brown, Jamie N, Brown, Lindsey T, Owenby Ryan K. "Use of Risperidone as Augmentation Treatment for Major Depressive Disorder." *Ann Pharmacotherapy.* January 2011. doi:10.1345/aph.1P397. Epub 2010 Dec 28.
67. College of Psychiatric and Neurologic Pharmacists. "Lithium Medication Fact Sheet" <https://cpnp.org/ed/presentation/2017/lithium-carbonate-and-citrate?view=link-medsheet-pdf>
68. Connolly MD, Ryan, Thase MD, Michael. "Unipolar Depression in Adults: Management of Highly Resistant (Refractory) Depression." *UpToDate*, August 31, 2021, https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression?search=adjunct%20for%20depression&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2
69. English, Clayton. (2020) *College of Psychiatric and Neurologic Pharmacists 2020-2021 Psychiatric Pharmacotherapy Review*. College of Psychiatric and Neurologic Pharmacists. Chapter 4: Depression, pg 206-267.
70. "Generalized Anxiety Disorder and Panic Disorder in Adults: Management." National Institute for Health and Care Excellence. Clinical Guideline. Published on Jan 26, 2011 Last Updated on July 26, 2019. <https://www.nice.org.uk/guidance/cg113/chapter/1-Guidance>
71. Lexicomp Topic 9566 Version 341.0 "Lithium: Drug Information." *UpToDate*, [https://www.uptodate.com/contents/lithium-](https://www.uptodate.com/contents/lithium-drug-)

[information?search=LITHIUM&source=panel_search_result&selectedTitle=1~149&usage_type=panel&kp_tab=drug_general&display_rank=1](#)

72. Nierenberg MD, Andrew. "Unipolar Major Depression in Adults: Augmentation of Antidepressants with stimulants and stimulant-like Drugs." *UpToDate*, March 30, 2021, https://www.uptodate.com/contents/unipolar-major-depression-in-adults-augmentation-of-antidepressants-with-stimulants-and-stimulant-like-drugs?search=adjunct%20for%20depression&topicRef=87500&source=see_link
73. "Pharmacology of Medicines for Treatments of Adults with Generalized Anxiety Disorder (GAD)." *UpToDate*
74. https://www.uptodate.com/contents/image?imageKey=PSYCH%2F77409&topicKey=PSYCH%2F101879&search=anxiety&rank=3~150&source=see_link